![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: John Wiley & Sons Inc
E-ISSN: 1099-1069|36|1|116-120
ISSN: 0278-0232
Source: Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 116-120
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma
Hematological Oncology (Electronic), Vol. 33, Iss. S1, 2015-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma
Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Rituximab in lymphocyte-predominant Hodgkin's disease
Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. :